Overview

Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease

Status:
Active, not recruiting

Trial end date:
2021-10-15

Target enrollment:

Participant gender:

Summary

The objective is to evaluate the efficacy and safety of once-daily oral doses of 10 mg elobixibat in combination with 9g cholestyramine powder (cholestyramine 4g) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

Phase:

Phase 2

Details

Lead Sponsor:

Yokohama City University

Collaborator:

EA Pharma Co., Ltd.

Treatments:

Cholestyramine Resin